Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 20/20 | 0.67 |
| ▸ | TYRO3 | Q06418 | 20/20 | 0.67 |
| ▸ | MERTK | Q12866 | 20/20 | 0.67 |
| ▸ | MET | P08581 | 15/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117682 | 0.94 | AXL (0.59) | AXLTYRO3MERTKMET | |
| SCHEMBL3103995 | 0.89 | AXL (0.58) | AXLTYRO3MERTKMET | |
| SCHEMBL30693661 | 0.89 | AXL (0.58) | AXLTYRO3MERTKMET | |
| SCHEMBL21777413 | 0.89 | AXL (0.68) | AXLTYRO3MERTKMET | |
| SCHEMBL3104308 | 0.89 | AXL (0.57) | AXLTYRO3MERTKMET | |
| SCHEMBL3108941 | 0.89 | AXL (0.57) | AXLTYRO3MERTKMET | |
| SCHEMBL21778136 | 0.87 | AXL (0.59) | AXLTYRO3MERTKMET | |
| SCHEMBL3111387 | 0.86 | AXL (0.62) | AXLTYRO3MERTKMET | |
| SCHEMBL21777621 | 0.86 | AXL (0.69) | AXLTYRO3MERTKMET | |
| SCHEMBL3097790 | 0.86 | AXL (0.60) | AXLTYRO3MERTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3843850-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | Array BioPharma Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-112930215-A | Pyrazolo [3, 4-b ] pyridine compounds as TAM and MET kinase inhibitors | 阿雷生物药品公司 | 2021-06-08 | — | — | CN | disclosed |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. | 2020-03-12 | — | — | US | disclosed |
| WO-2020047184-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AXL 20/4885TYRO3 8/4885MERTK 2/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AXL 14/4885TYRO3 7/4885MERTK 2/4885 |
| US-20200079770-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | AXL 14/4885TYRO3 7/4885MERTK 2/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | AXL 20/4885TYRO3 8/4885MERTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.